OptheaOPT
Market Cap: $594M
About: Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company geographically operates Australia and United States.
Employees: 34
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
13% more funds holding
Funds holding: 8 [Q1] → 9 (+1) [Q2]
0.05% less ownership
Funds ownership: 1.01% [Q1] → 0.96% (-0.05%) [Q2]
55% less capital invested
Capital invested by funds: $27.5M [Q1] → $12.2M (-$15.3M) [Q2]
80% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 5
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
HC Wainwright & Co. Matthew Caufield 36% 1-year accuracy 15 / 42 met price target | 211%upside $12 | Buy Maintained | 3 Sept 2024 |
Financial journalist opinion
Based on 5 articles about OPT published over the past 30 days